DG Capital Management (Massachusetts)’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q3
$2.99M Buy
37,235
+4,785
+15% +$383K 2.94% 7
2016
Q2
$2.56M Buy
32,450
+540
+2% +$40.7K 2.73% 9
2016
Q1
$2.3M Sell
31,910
-21,675
-40% -$1.64M 2.25% 14
2015
Q4
$4.51M Sell
53,585
-16,365
-23% -$1.36M 4.03% 3
2015
Q3
$5.85M Sell
69,950
-7,485
-10% -$632K 3.94% 1
2015
Q2
$6.46M Sell
77,435
-1,660
-2% -$126K 3.9% 2
2015
Q1
$5.75M Buy
79,095
+20,455
+35% +$1.46M 3.46% 3
2014
Q4
$4.05M Sell
58,640
-6,125
-9% -$413K 2.34% 10
2014
Q3
$4.2M Buy
64,765
+2,735
+4% +$173K 2.56% 7
2014
Q2
$3.86M Sell
62,030
-8,245
-12% -$492K 2.2% 8
2014
Q1
$4.14M Buy
+70,275
New +$3.92M 2.45% 8
2013
Q4
Sell
-43,260
Closed -$2.18M 67
2013
Q3
$2.18M Sell
43,260
-9,270
-18% -$485K 1.23% 46
2013
Q2
$2.58M Buy
+52,530
New +$2.86M 1.56% 39

Other funds holding LLY

DG Capital Management (Massachusetts)'s LLY Position: Q3 2016 in Review

DG Capital Management (Massachusetts) increased its Eli Lilly (LLY) stake by 15% in Q3 2016, buying an estimated $383K and bringing the position to 37,235 shares worth $2.99M. The position accounts for 2.94% of the portfolio, ranked #7.

DG Capital Management (Massachusetts) first reported a position in LLY in Q2 2013 and has held it in 13 quarters since. The position peaked at $6.46M in Q2 2015. 1,176 funds tracked by Wall St. Rank hold LLY as of Q3 2016.

  • DG Capital Management (Massachusetts) held 37,235 shares of Eli Lilly worth $2.99M as of Q3 2016.
  • DG Capital Management (Massachusetts) bought 4,785 Eli Lilly shares in Q3 2016, an estimated $383K.
  • Eli Lilly made up 2.94% of DG Capital Management (Massachusetts)'s portfolio in Q3 2016, its #7 holding.
  • DG Capital Management (Massachusetts) first reported a position in Eli Lilly in Q2 2013 and has held it in 13 quarters since.
  • DG Capital Management (Massachusetts)'s Eli Lilly position peaked at $6.46M in Q2 2015.
  • 1,176 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2016.

Based on DG Capital Management (Massachusetts)'s 13F filing for Q3 2016, filed 21 Oct 2016.